Antiviral Effects of Heparan Sulfate and Enoxaparin Against SARS-CoV-2
Author Information
Author(s): Virginia Fuochi, Salvatore Furnari, Giuseppe Floresta, Vincenzo Patamia, Chiara Zagni, Filippo Drago, Antonio Rescifina, Pio Maria Furneri
Primary Institution: University of Catania
Hypothesis
Heparan sulfate and enoxaparin can inhibit the entry of SARS-CoV-2 into host cells.
Conclusion
Heparan sulfate and enoxaparin effectively inhibit the entry of SARS-CoV-2 into cells, suggesting their potential as antiviral agents.
Supporting Evidence
- Heparan sulfate showed minimal cytotoxic effects on A549 cells.
- Enoxaparin exhibited cytotoxicity at higher concentrations but was safe at lower doses.
- Both substances significantly inhibited viral entry in various treatment scenarios.
Takeaway
This study shows that two substances, heparan sulfate and enoxaparin, can help stop the COVID-19 virus from getting into our cells.
Methodology
The study used in-vitro assays to evaluate the antiviral activity of heparan sulfate and enoxaparin against SARS-CoV-2, including cytotoxicity tests and viral entry assays.
Limitations
The study primarily focused on in-vitro results, which may not fully translate to in-vivo efficacy.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website